2024
Elevated myocardial extracellular volume fraction is associated with the development of conduction pathway defects following transcatheter aortic valve replacement
Feroze R, Kang P, Dallan L, Akula N, Galo J, Yoon S, Ukaigwe A, Filby S, Baeza C, Pelletier M, Rushing G, Rajagopalan S, Al‐Kindi S, Rashid I, Attizzani G. Elevated myocardial extracellular volume fraction is associated with the development of conduction pathway defects following transcatheter aortic valve replacement. Catheterization And Cardiovascular Interventions 2024, 104: 1119-1128. PMID: 38952304, DOI: 10.1002/ccd.31136.Peer-Reviewed Original ResearchMeSH KeywordsAction PotentialsAgedAged, 80 and overAortic ValveAortic Valve StenosisArea Under CurveAtrioventricular BlockBundle-Branch BlockCardiac Pacing, ArtificialFemaleFibrosisHeart Conduction SystemHumansMagnetic Resonance Imaging, CineMaleMyocardiumPacemaker, ArtificialPredictive Value of TestsRetrospective StudiesRisk AssessmentRisk FactorsROC CurveTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeConceptsTranscatheter aortic valve replacementCardiac magnetic resonance imagingLate gadolinium enhancementRight bundle branch blockArea under the receiver operating characteristic curveAortic valve replacementReceiver operating curveMyocardial fibrosisPost-TAVRConduction defectsBundle branch blockAssociations of myocardial fibrosisExtracellular volumeConduction diseaseValve replacementGadolinium enhancementPermanent pacemakerConduction abnormalitiesConduction deficitsHeart blockBranch blockRisk of heart blockSeptal late gadolinium enhancementMyocardial extracellular volume fractionBaseline conduction disease
2023
Clinical impact of right ventricular pacing burden in patients with post-transcatheter aortic valve replacement permanent pacemaker implantation
Tsushima T, Al-Kindi S, Dallan L, Fares A, Yoon S, Wheat H, Attizzani G, Baeza C, Pelletier M, Arruda M, Mackall J, Thal S. Clinical impact of right ventricular pacing burden in patients with post-transcatheter aortic valve replacement permanent pacemaker implantation. EP Europace 2023, 25: 1441-1450. PMID: 36794441, PMCID: PMC10105841, DOI: 10.1093/europace/euad025.Peer-Reviewed Original ResearchConceptsRight ventricular pacing burdenTranscatheter aortic valve replacementVentricular pacing burdenPermanent pacemaker implantationPermanent pacemakerHeart failurePacing burdenPPM implantationRetrospective study of consecutive patientsLikelihood of heart failureStudy of consecutive patientsLeft ventricular ejection fractionAssociated with worse outcomesVentricular ejection fractionAortic valve replacementAtrial fibrillation burdenValve implantation depthConsecutive patientsEjection fractionValve replacementPost-TAVRClinical benefitPacemaker implantationRetrospective studySingle-centre
2017
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomized Clinical Trial
Rodés-Cabau J, Masson J, Welsh R, del Blanco B, Pelletier M, Webb J, Al-Qoofi F, Généreux P, Maluenda G, Thoenes M, Paradis J, Chamandi C, Serra V, Dumont E, Côté M. Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomized Clinical Trial. JACC Cardiovascular Interventions 2017, 10: 1357-1365. PMID: 28527771, DOI: 10.1016/j.jcin.2017.04.014.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic ValveAspirinBalloon ValvuloplastyCanadaClopidogrelDrug Therapy, CombinationEarly Termination of Clinical TrialsEuropeFemaleFibrinolytic AgentsHeart Valve ProsthesisHemorrhageHumansIschemic Attack, TransientKaplan-Meier EstimateMaleMyocardial InfarctionPlatelet Aggregation InhibitorsProsthesis DesignRisk FactorsSouth AmericaStrokeThrombosisTiclopidineTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeConceptsTranscatheter aortic valve replacementTransient ischemic attackLife-threatening bleedingAortic valve replacementBalloon-expandable valveOccurrence of deathMyocardial infarctionIschemic attackBleeding eventsValve replacementAntithrombotic treatmentClinical trialsLife-threatening bleeding eventsPrevention of ischemic eventsOptimal antithrombotic therapyComposite of deathRandomized clinical trialsPlanned study populationLife-threatening eventsRandomized controlled trialsCompared aspirinPrimary endpointAntithrombotic therapyPost-TAVRAdverse events
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply